Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Decision Resources Group
Decision Resources Group
Activities:
Media
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Media
Chilean pharmaceutical market expected to increase at CAGR of 11.3% over next five years
Pharma landscape is small but highly competitive, finds new report from Decision Resources Group
You need to be a subscriber to read this article.
Click here
to find out more.
Drug Delivery
Drug delivery innovations set to disrupt sector
Drug formulators will have a broader range of drug delivery options in future, aiding both compliance and outcomes. Susan Birks reports
Media
Colombian pharmaceutical market expected to reach US$5.37bn by 2016
Provides an entry point into South America for multinational pharmaceutical companies
Vietnam bans companies making \'substandard\' drugs
Companies banned include 45 Indian pharmaceutical companies along with others from Korea, France and Pakistan
Media
Global biosimilars pipeline has expanded by more than 40% in 12 months, finds report
Strong growth in Brazil driven by public-private partnerships
Pharmaceutical
Biosimilars
9 April 2014, One-day seminar, London, UK
Media
Piramal Healthcare buys Decision Resources Group
Indian firm pays US$635m for healthcare information business
Subscribe now